The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, speaks on a multi-center trial (NCT03277729) evaluating a third-generation CD20-targeted CAR-T product (MB-106) in the treatment of indolent B-cell lymphomas, including Waldenström’s macroglobulinemia (WM). The CAR-T product holds FDA orphan drug designation for WM, and the eagerly anticipated trial results are expected to demonstrate promising safety and efficacy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, Fate Therapeutics, Janssen, Kite, a Gilead Company, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, ADC therapeutics, Genentech, AbbVie, MEI Pharma, Regeneron; Research Funding: BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, Vincerx, Genentech, AbbVie, TG Therapeutics.
